887115-56-2

Basic information

• Product Name: 5-Bromo-1-methyl-1H-pyrazolo[3,4-b]pyridine
• Synonyms: 5-Bromo-1-methyl-1H-pyrazolo[3,4-b]pyridine;5-Bromo-1-methyl-1H-pyraz...;5-bromo-1-methylpyrazolo[3,4-b]pyridine
• CAS NO: 887115-56-2
• Molecular Formula: C₇H₆BrN₃
• Molecular Weight: 212.04664
• Mol File: 887115-56-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-Bromo-1-methyl-1H-pyrazolo[3,4-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-1-methyl-1H-pyrazolo[3,4-b]pyridine(887115-56-2)
• EPA Substance Registry System: 5-Bromo-1-methyl-1H-pyrazolo[3,4-b]pyridine(887115-56-2)

Safety Data

• Hazardous Substances Data: 887115-56-2(Hazardous Substances Data)

Usage

General Description

5-Bromo-1-methyl-1H-pyrazolo[3,4-b]pyridine, also known as BEMP, is a chemical compound with a molecular formula C7H6BrN3. It is a heterocyclic aromatic compound with a pyrazole ring fused to a pyridine ring. BEMP is commonly used as a building block or intermediate in the synthesis of pharmaceuticals and agrochemicals. It has also been studied for its potential applications in medicinal chemistry, particularly as a scaffold for the development of new drug molecules. BEMP is considered to be a useful and versatile chemical with potential for a wide range of applications in the fields of chemistry and medicine.

Upstream product

• 875781-17-2 5-bromo-7-azaindazole 
• 74-88-4 methyl iodide 
• 2065-75-0 2-Bromo-malonaldehyde 
• 1192-21-8 5-Amino-1-methylpyrazole 

Downstream Products

• 1421684-98-1 C₃₀H₂₉F₃N₆O 

Relevant articles and documents

Solvent-Controlled, Site-Selective N-Alkylation Reactions of Azolo-Fused Ring Heterocycles at N1-, N2-, and N3-Positions, Including Pyrazolo[3,4- d]pyrimidines, Purines, [1,2,3]Triazolo[4,5]pyridines, and Related Deaza-Compounds

Alkylation of 4-methoxy-1H-pyrazolo[3,4-d]pyrimidine (1b) with iodomethane in THF using NaHMDS as base selectively provided N2-methyl product 4-methoxy-2-methyl-2H-pyrazolo[3,4-d]pyrimidine (3b) in an 8/1 ratio over N1-methyl product (2b). Interestingly, conducting the reaction in DMSO reversed selectivity to provide a 4/1 ratio of N1/N2 methylated products. Crystal structures of product 3b with N1 and N7 coordinated to sodium indicated a potential role for the latter reinforcing the N2-selectivity. Limits of selectivity were tested with 26 heterocycles which revealed that N7 was a controlling element directing alkylations to favor N2 for pyrazolo- and N3 for imidazo- and triazolo-fused ring heterocycles when conducted in THF. Use of 1H-detected pulsed field gradient-stimulated echo (PFG-STE) NMR defined the molecular weights of ionic reactive complexes. This data and DFT charge distribution calculations suggest close ion pairs (CIPs) or tight ion pairs (TIPs) control alkylation selectivity in THF and solvent-separated ion pairs (SIPs) are the reactive species in DMSO.

NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS

The present invention is directed to novel compounds of formula (I) and their use in treating metabolic diseases.